These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 25001321

  • 21. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF.
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [Abstract] [Full Text] [Related]

  • 22. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D, Berk AT, Micili SC, Kume T, Ergur BU, Yilmaz O.
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [Abstract] [Full Text] [Related]

  • 23. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.
    Messenger WB, Campbell JP, Faridi A, Shippey L, Bailey ST, Lauer AK, Flaxel CJ, Hwang TS.
    Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334
    [Abstract] [Full Text] [Related]

  • 24. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB.
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [Abstract] [Full Text] [Related]

  • 25. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J, Peng RS, Xu D, Li YH, Shi H, Wang Q, Yu J.
    Drug Des Devel Ther; 2015 Jul; 9():5397-405. PubMed ID: 26451092
    [Abstract] [Full Text] [Related]

  • 26. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
    Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW, Williams GA.
    Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
    [Abstract] [Full Text] [Related]

  • 27. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA, Gaffney EA, Byrne HM, Maini PK, Schwab D, Mazer NA.
    Mol Pharm; 2016 Sep 06; 13(9):2941-50. PubMed ID: 26726925
    [Abstract] [Full Text] [Related]

  • 28. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
    Low A, Faridi A, Bhavsar KV, Cockerham GC, Freeman M, Fu R, Paynter R, Kondo K, Kansagara D.
    Br J Ophthalmol; 2019 Apr 06; 103(4):442-451. PubMed ID: 30409915
    [Abstract] [Full Text] [Related]

  • 29. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K, Fraser-Bell S, Hong T, Chang A.
    Clin Exp Ophthalmol; 2020 Jan 06; 48(1):53-60. PubMed ID: 31498950
    [Abstract] [Full Text] [Related]

  • 30. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB.
    Am J Ophthalmol; 2013 Jul 06; 156(1):15-22.e1. PubMed ID: 23706500
    [Abstract] [Full Text] [Related]

  • 31. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC, Lee DK, Kim SH, You YS, Kwon OW.
    Korean J Ophthalmol; 2015 Aug 06; 29(4):226-32. PubMed ID: 26240506
    [Abstract] [Full Text] [Related]

  • 32. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
    Thorell MR, Nunes RP, Chen GW, Doshi RR, Dugar J, George MK, Kim BT, Lowrance MD, Modi D, Nahas Z, Gregori G, Yehoshua Z, Feuer W, Rosenfeld PJ.
    Ophthalmic Surg Lasers Imaging Retina; 2014 Aug 06; 45(6):526-33. PubMed ID: 25423632
    [Abstract] [Full Text] [Related]

  • 33. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A, Parikh VS, Singh RP, Ehlers JP, Yuan A, Rachitskaya AV, Sears JE, Srivastava SK, Kaiser PK, Schachat AP, Martin DF, Modi Y.
    Br J Ophthalmol; 2017 Jul 06; 101(7):970-975. PubMed ID: 27913442
    [Abstract] [Full Text] [Related]

  • 34. CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Angermann R, Huber AL, Nowosielski Y, Salcher S, Gasser T, Seifarth C, Kralinger MT, Zehetner C.
    Retina; 2022 Mar 01; 42(3):503-510. PubMed ID: 34731094
    [Abstract] [Full Text] [Related]

  • 35. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N, Rahimy E, Storey P, Shah CP, Wolfe JD, Chen E, DeCroos FC, Garg SJ, Hsu J.
    Am J Ophthalmol; 2016 May 01; 165():88-93. PubMed ID: 26944277
    [Abstract] [Full Text] [Related]

  • 36. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M, Todorova MG, Masyk M, Wolf K, Rickmann A, Helaiwa K, Blanke BR, Szurman P.
    BMC Ophthalmol; 2017 May 23; 17(1):79. PubMed ID: 28535756
    [Abstract] [Full Text] [Related]

  • 37. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
    Rusu IM, Deobhakta A, Yoon D, Lee M, Slakter JS, Klancnik JM, Thompson D, Freund KB.
    Retina; 2014 Nov 23; 34(11):2161-6. PubMed ID: 25072648
    [Abstract] [Full Text] [Related]

  • 38. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
    Elshout M, van der Reis MI, Webers CA, Schouten JS.
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec 23; 252(12):1911-20. PubMed ID: 24777708
    [Abstract] [Full Text] [Related]

  • 39. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ.
    Ophthalmology; 2017 Mar 23; 124(3):352-358. PubMed ID: 27890437
    [Abstract] [Full Text] [Related]

  • 40. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
    Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, VIEW 1 and VIEW 2 Study Groups.
    Ophthalmology; 2012 Dec 23; 119(12):2537-48. PubMed ID: 23084240
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.